Results for tag: "Nerlynx"

Nerlynx (neratinib) is a targeted therapy drug used to treat certain types of breast cancer. It is a type of tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that help cancer cells grow and divide. It is used to treat early-stage HER2-positive breast cancer after surgery and chemotherapy, and is also used to treat advanced HER2-positive breast cancer in combination with other drugs. Nerlynx is approved by the U.S. Food and Drug Administration (FDA) and is available in the United States, Europe, and other countries. The Nerlynx market is a rapidly growing segment of the breast cancer drug market. It is estimated that the global Nerlynx market will reach $1.2 billion by 2027, driven by the increasing prevalence of breast cancer and the growing demand for targeted therapies. Companies in the Nerlynx market include Puma Biotechnology, Inc., AstraZeneca, and Daiichi Sankyo. Show Less Read more